Linkedin
RLS logo_header
Linkedin

TOP STORIES from the week

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology

IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review

Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients

IND-enabling studies for BEA 17 initiated in GBM

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer

FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

End-of-Phase 1 Type B meeting concerning NEO212 scheduled with FDA

Complete and Durable Responses in R/R ALL Patients Treated with VNX-101 Announced

Enrollment underway in Randomized REO 033 RAS-Mutant, MSS CRC Study

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer

Stay up to date with OTW

Get all oncology clinical development news in your inbox

Drug approvals

FDA Approves Lyrfigtu (Lirafugratinib) for 2L Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option

FDA approves BRAVNETSA™ (lutetium Lu 177 dotatate) for patients with SSR+ve GEP-NETs, including foregut, midgut, and hindgut NEC tumors

FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC

FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Regulatory news

IND-enabling studies for BEA 17 initiated in GBM

End-of-Phase 1 Type B meeting concerning NEO212 scheduled with FDA

Regulatory Update on Tovecimig in BTC Following FDA Feedback Provided

SOT106 granted fast Track Designation in osteosarcoma and orphan Drug Designation granted in soft tissue sarcoma

Trial results

Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients

Complete and Durable Responses in R/R ALL Patients Treated with VNX-101 Announced

Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line RRMM

trial status

IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review

Enrollment underway in Randomized REO 033 RAS-Mutant, MSS CRC Study

Pivotal Ph 3 THIO-104 NSCLC Trial expanded into Spain and Portugal

Enrollment underway in pivotal Ph 3 THIO-104 trial in 3L NSCLC patients

Business news

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance ADC combination strategy in cancer

Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

Archive

2025

2024

2023

2022

2021

2020

2019

2018